No Data
No Data
Express News | Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to Its Board of Directors
Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to Its Board of Directors
JMP Securities Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $13
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Foghorn Therapeutics Announces New Preclinical Data at AACR